Anixa Biosciences
Tracked across 2 events · 12 articles · First seen Apr 02, 2026 · Last active Sep 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Anixa Biosciences announced that Australia — Australian Government issued Patent Number 2020221280, a composition-of-matter patent titled Vaccine Adjuvants and Formulations, covering its breast cancer vaccine technology in Australia through 2040. The technology is exclusively licensed…
Impact: Anixa is the central actor, receiving the Australian composition-of-matter patent through 2040 for its breast cancer vaccine and expanding its global IP estate. The grant supports future regulatory and partnering prospects, though the stock traded down about 2 percent on the day.
Sep 21, 2026 · 6 articles
Business
Impact: Anixa Biosciences presented at the Biotech Resurgence conference, offering insights into its clinical development strategies and pipeline progress.
Apr 20, 2026 · 6 articles
60
Anixa Biosciences licensed vaccine technology Cleveland ClinicAnixa Australian Patent...
55
Anixa Biosciences completed Phase 1 trialAnixa Australian Patent...
ERGEN INTELLIGENCE
Track Anixa Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard